Roivant Sciences Ltd.
ROIV
Rank in Stocks
#980
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company... Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
Share Price
$33.73
Last synced: 2026-07-31
Market Cap
$24.37B
Change (1 day)
-2.28%
Change (1 year)
90.15%
Country
GB
Trade Roivant Sciences Ltd. (ROIV)
Category
Healthcare
Earnings for Roivant Sciences Ltd. (ROIV)
Earnings in Jun 2026 TTM: $-289.88M
According to Roivant Sciences Ltd. latest financial reports the company's current earnings are $-289.88M. In 2024 the company made an earning of $4.57B, an increase over its 2023 earnings that were of $-1.22B. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Roivant Sciences Ltd. from 2020 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| 2026 (TTM) | $-289.88M | -57.47% |
| 2025 | $-681.59M | -114.92% |
| 2024 | $4.57B | -472.94% |
| 2023 | $-1.22B | 32.59% |
| 2022 | $-923.75M | 2.80% |
| 2021 | $-898.55M | 60.17% |
| 2020 | $-560.99M | 0.00% |
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| $5.27B | -1,919.68% |
US
|
|
| $-3.09B | 964.92% |
US
|
|
| $-4.02B | 1,285.47% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -772.92% |
NL
|
